Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00002641CT.gov Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pheochromocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB · 64 |
| Adriamycin | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Isocyclophosphamide | European Organisation for Research and Treatment of Cancer - EORTC | P3 | BB |
| Tamoxifen | Ottawa Regional Cancer Centre | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Ottawa Regional Cancer Centre | P2 | B |
| Fostamatinib Disodium | National Cancer Institute (NCI) | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Vanderbilt-Ingram Cancer Center | P2 | CCC |
| Guadecitabine | National Cancer Institute (NCI) | P2 | CCC |
| Edotreotide | Excel Diagnostics and Nuclear Oncology Center | P2 | CCC |
+13 more in the Pheochromocytoma cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- IsocyclophosphamideEuropean Organisation for Research and Treatment of Cancer - EORTCBB
- TamoxifenOttawa Regional Cancer CentreB
- Cis-Diamminedichloroplatinum IiOttawa Regional Cancer CentreB
- Fostamatinib DisodiumNational Cancer Institute (NCI)B
Citation
Floatz Terminal. Nivestim in Pheochromocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-pheochromocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →